200 related articles for article (PubMed ID: 36404640)
1. Early myocardial oedema can predict subsequent cardiomyopathy in high-dose anthracycline therapy.
Muehlberg F; Kornfeld M; Zange L; Ghani S; Reichardt A; Reichardt P; Schulz-Menger J
ESC Heart Fail; 2023 Feb; 10(1):616-627. PubMed ID: 36404640
[TBL] [Abstract][Full Text] [Related]
2. Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy.
Muehlberg F; Funk S; Zange L; von Knobelsdorff-Brenkenhoff F; Blaszczyk E; Schulz A; Ghani S; Reichardt A; Reichardt P; Schulz-Menger J
ESC Heart Fail; 2018 Aug; 5(4):620-629. PubMed ID: 29673122
[TBL] [Abstract][Full Text] [Related]
3. Ultrahigh-field cardiovascular magnetic resonance T1 and T2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changes.
Park HS; Hong YJ; Han K; Kim PK; An E; Lee JY; Park CH; Lee HJ; Hur J; Kim YJ; Choi BW
J Cardiovasc Magn Reson; 2021 Jun; 23(1):76. PubMed ID: 34134713
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular magnetic resonance characterisation of anthracycline cardiotoxicity in adults with normal left ventricular ejection fraction.
Harries I; Berlot B; Ffrench-Constant N; Williams M; Liang K; De Garate E; Baritussio A; Biglino G; Plana JC; Bucciarelli-Ducci C
Int J Cardiol; 2021 Nov; 343():180-186. PubMed ID: 34454967
[TBL] [Abstract][Full Text] [Related]
5. Prospective multiparametric CMR characterization and MicroRNA profiling of anthracycline cardiotoxicity: A pilot translational study.
Harries I; Biglino G; Ford K; Nelson M; Rego G; Srivastava P; Williams M; Berlot B; De Garate E; Baritussio A; Liang K; Baquedano M; Chavda N; Lawton C; Shearn A; Otton S; Lowry L; Nightingale AK; Carlos Plana J; Marks D; Emmanueli C; Bucciarelli-Ducci C
Int J Cardiol Heart Vasc; 2022 Dec; 43():101134. PubMed ID: 36389268
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer.
Thavendiranathan P; Shalmon T; Fan CS; Houbois C; Amir E; Thevakumaran Y; Somerset E; Malowany JM; Urzua-Fresno C; Yip P; McIntosh C; Sussman MS; Brezden-Masley C; Yan AT; Koch CA; Spiller N; Abdel-Qadir H; Power C; Hanneman K; Wintersperger BJ
JAMA Cardiol; 2023 Jun; 8(6):524-534. PubMed ID: 37043251
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.
Ferreira de Souza T; Quinaglia A C Silva T; Osorio Costa F; Shah R; Neilan TG; Velloso L; Nadruz W; Brenelli F; Sposito AC; Matos-Souza JR; Cendes F; Coelho OR; Jerosch-Herold M; Coelho-Filho OR
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1045-1055. PubMed ID: 30092965
[TBL] [Abstract][Full Text] [Related]
8. Serial Cardiac MRI for Quantification of the Dynamics of Anthracycline-Induced Subclinical Myocardial Injury.
Zheng Y; Liu H; Zhao L; Guan S; Huo H; Li H; Guo J; Peng X; Hao Y; Jin S; Hou Y; Dai X; Liu T; Zhang X
J Magn Reson Imaging; 2023 Nov; 58(5):1533-1541. PubMed ID: 36912379
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors.
Jordan JH; Vasu S; Morgan TM; D'Agostino RB; Meléndez GC; Hamilton CA; Arai AE; Liu S; Liu CY; Lima JA; Bluemke DA; Burke GL; Hundley WG
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27502058
[TBL] [Abstract][Full Text] [Related]
10. Candidate Plasma Biomarkers to Detect Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors: A Case Control Study in the Dutch Childhood Cancer Survivor Study.
Leerink JM; Feijen EAM; Moerland PD; de Baat EC; Merkx R; van der Pal HJH; Tissing WJE; Louwerens M; van den Heuvel-Eibrink MM; Versluys AB; Asselbergs FW; Sammani A; Teske AJ; van Dalen EC; van der Heiden-van der Loo M; van Dulmen-den Broeder E; de Vries ACH; Kapusta L; Loonen J; Pinto YM; Kremer LCM; Mavinkurve-Groothuis AMC; Kok WEM
J Am Heart Assoc; 2022 Jul; 11(14):e025935. PubMed ID: 35861824
[TBL] [Abstract][Full Text] [Related]
11. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
[TBL] [Abstract][Full Text] [Related]
12. Characterization of critically ill patients with septic shock and sepsis-associated cardiomyopathy using cardiovascular MRI.
Muehlberg F; Blaszczyk E; Will K; Wilczek S; Brederlau J; Schulz-Menger J
ESC Heart Fail; 2022 Aug; 9(4):2147-2156. PubMed ID: 35587684
[TBL] [Abstract][Full Text] [Related]
13. Left atrial reservoir longitudinal strain and its incremental value to the left ventricular global longitudinal strain in predicting anthracycline-induced cardiotoxicity.
Li Z; Zhao R; Zhang Q; Shen Y; Shu X; Cheng L
Echocardiography; 2024 Apr; 41(4):e15805. PubMed ID: 38558436
[TBL] [Abstract][Full Text] [Related]
14. Cardiac magnetic relaxometry versus ejection fraction in anthracycline-related cardiac changes: a systematic review and meta-analysis.
Yu C; Pathan S; Jeyaprakash P; Kritharides L; Pathan F; Negishi K
Open Heart; 2023 Jul; 10(2):. PubMed ID: 37507150
[TBL] [Abstract][Full Text] [Related]
15. Cardiac MRI Myocardial Functional and Tissue Characterization Detects Early Cardiac Dysfunction in a Mouse Model of Chemotherapy-Induced Cardiotoxicity.
Naresh NK; Misener S; Zhang Z; Yang C; Ruh A; Bertolino N; Epstein FH; Collins JD; Markl M; Procissi D; Carr JC; Allen BA
NMR Biomed; 2020 Sep; 33(9):e4327. PubMed ID: 32567177
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of anthracycline-induced myocardial injury using serial cardiac magnetic resonance: An animal study.
Wang R; Zhou Z; Schoepf UJ; Varga-Szemes A; Strigenz A; Wang H; Liu Y; Xu L
Int J Cardiol; 2021 Apr; 328():111-116. PubMed ID: 33359332
[TBL] [Abstract][Full Text] [Related]
17. Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity.
Galán-Arriola C; Lobo M; Vílchez-Tschischke JP; López GJ; de Molina-Iracheta A; Pérez-Martínez C; Agüero J; Fernández-Jiménez R; Martín-García A; Oliver E; Villena-Gutierrez R; Pizarro G; Sánchez PL; Fuster V; Sánchez-González J; Ibanez B
J Am Coll Cardiol; 2019 Feb; 73(7):779-791. PubMed ID: 30784671
[TBL] [Abstract][Full Text] [Related]
18. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.
Thavendiranathan P; Houbois C; Marwick TH; Kei T; Saha S; Runeckles K; Huang F; Shalmon T; Thorpe KE; Pezo RC; Prica A; Maze D; Abdel-Qadir H; Connelly KA; Chan J; Billia F; Power C; Hanneman K; Wintersperger BJ; Brezden-Masley C; Amir E
Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):515-525. PubMed ID: 37120736
[TBL] [Abstract][Full Text] [Related]
19. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling.
Tham EB; Haykowsky MJ; Chow K; Spavor M; Kaneko S; Khoo NS; Pagano JJ; Mackie AS; Thompson RB
J Cardiovasc Magn Reson; 2013 Jun; 15(1):48. PubMed ID: 23758789
[TBL] [Abstract][Full Text] [Related]
20. Effect of anthracycline therapy on myocardial function and markers of fibrotic remodelling in childhood cancer survivors.
Mawad W; Mertens L; Pagano JJ; Riesenkampff E; Reichert MJE; Mital S; Kantor PF; Greenberg M; Liu P; Nathan PC; Grosse-Wortmann L
Eur Heart J Cardiovasc Imaging; 2021 Mar; 22(4):435-442. PubMed ID: 32535624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
